Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), a Montreal-based biotechnology and precision intracellular drug-delivery company, has invited shareholders to its Annual General Meeting on December 10, 2026, in Montreal, Quebec, with virtual attendance also available. The meeting will be the first AGM held under the leadership of Dr. Amie Phinney, who assumed the role of President and Chief Executive Officer in August 2026. Management will address strategic priorities and outline the company's plans and outlook for 2027, making the event of particular interest to investors tracking Defence's near-term direction.

Key Points

  • Defence Therapeutics Inc. (CSE: DTC) is a publicly traded biotechnology company focused on precision intracellular drug delivery
  • The Annual General Meeting is scheduled for December 10, 2026, at 11:00 a.m. ET in Montreal, Quebec, with virtual participation available via Microsoft Teams
  • Proxy voting deadline for registered shareholders is 11:00 a.m. ET on December 8, 2026; the record date for voting eligibility was November 2, 2026
  • Investors may watch for strategic commentary from CEO Dr. Amie Phinney on the company's 2027 plans and progress on its Accum® drug-delivery platform

Defence Therapeutics AGM Details: Date, Location, and Virtual Access

The meeting will take place at Suite 2700 – 1000 Sherbrooke Street West, Montreal, Quebec, on December 10, 2026, beginning at 11:00 a.m. ET. Shareholders who cannot attend in person may listen and participate in real time through Microsoft Teams using the Teams Meeting ID: 260 258 498 001 400 6. The company notes that voting will not be available through the virtual platform, and shareholders attending remotely are encouraged to submit proxy voting instructions in advance. The Materials, including the information circular and proxy form, have been mailed to eligible shareholders and are available on the company's website.

First AGM Under CEO Dr. Amie Phinney and the 2027 Strategic Outlook

The December 10 meeting marks a notable milestone for Defence Therapeutics, as it will be the first Annual General Meeting conducted under the leadership of Dr. Amie Phinney, who took on the President and Chief Executive Officer role in August 2026. Dr. Phinney and members of the leadership team plan to attend in person and present an update on the company's progress against its strategic priorities, along with plans and an outlook for 2027. The company did not disclose specific financial targets or operational milestones in the announcement.

Accum® Platform Underpins Defence Therapeutics' Oncology Focus

Defence Therapeutics develops cancer therapies using its proprietary Accum® precision drug-delivery platform, which is designed to enhance the potency of antibody-drug conjugates and other complex biologics at lower doses. The company's stated goal is to reduce treatment-related side effects and improve patient access to advanced oncology therapies. Defence also pursues partnerships with pharmaceutical and biotechnology companies to advance its technology, positioning the platform as a potential collaboration asset within the growing ADC sector.